fda bpc-157 warning letter compounding Pharmacy Committee Votes on Peptide Policy | John Hoekman posted on the topic July 23-24, 2026: Meeting of
Description
X-rays for bony changes
Bourne JT, Baker ADL, Khatri M
Their limitation is not their mechanism
Not marketing claims
It is an advisory committee meeting to discuss whether certain substances should be considered for a compounding list, and such committees issue non-binding recommendations [10]
